The objective of this phase II study is to examine the efficacy and safety of sacituzumab govitecan, an antibody–drug conjugate targeting Trop-2, in the metastatic urothelial carcinoma setting. One cohort of the trial includes patients who have progressed after platinum-based chemotherapy and checkpoint inhibitor therapy, while the other has cisplatin-ineligible individuals who have progressed on immunotherapy.
Initial results, presented at the ESMO Congress 2019, confirm the antitumor activity of sacituzumab govitecan in patients with mUC that has progressed after platinum chemotherapy or checkpoint inhibition.